Rhythm: Why “Up to $134” Is Not Cash in Hand

A reported acquisition approach raises three separate questions: what is being offered, what must happen before payment, and what that payment is worth today.

A precise acquisition number can make an uncertain situation feel settled. “Up to $134 per share” sounds like a destination. For investors, it is the beginning of the analysis.

Reuters reported on November 4, citing people familiar with the matter, that AstraZeneca had made a non-binding proposal for Rhythm Pharmaceuticals offering as much as $134 per share including milestone payments. This note treats the approach as reported information, not an announced, signed acquisition agreement.[1]

Two conditions sit inside the headline

The first is whether a transaction will happen. A non-binding proposal does not, by itself, establish an obligation to complete an acquisition on those terms. The parties may still need to agree on price, diligence, financing arrangements and legal terms. A signed definitive agreement would establish contractual obligations, but closing could still depend on shareholder approval, regulatory clearance and other specified conditions.[2]

The second is whether every component of the proposed consideration will be paid. Milestone-linked consideration depends on agreed events. Even a completed acquisition may therefore leave shareholders with less than the stated maximum.

Those uncertainties require separate judgments. Confidence that a deal will close is not the same as confidence that every subsequent milestone will be achieved.

The reported maximum is neither a guaranteed payment nor a permanent ceiling on future negotiations. Terms could change, a different offer could emerge, or there could be no acquisition.

The missing split matters

The Reuters report does not provide enough detail to reconstruct the fixed and contingent portions of the reported $134 proposal. Its separate reference to an earlier $124 offer does not establish that the later proposal consists of $124 in cash plus a $10 milestone payment. We should not manufacture a payment schedule by subtracting two reported numbers.[1]

The legal instrument also matters. Milestone-linked consideration might be documented through a contingent value right or another contractual mechanism, but the report alone does not establish a CVR structure, transferability, deadlines or enforcement rights.

• Cash or other consideration due at closing: Establishes what a completed transaction would initially deliver.

• Milestone amount and precise trigger: Separates a possible payout from an obligation already due.

• Deadline and payment timing: An identical nominal amount can have a different present value.

• Post-acquisition development obligations and enforcement: Helps assess how future investment decisions could affect achievement.

• Conditions to closing and termination rights: Defines when the acquisition itself can proceed or end.

Use an illustration, not an invented Rhythm model

Consider an entirely hypothetical offer: $120 per share at closing and another $14 if a specified milestone is achieved three years after closing. These are teaching assumptions, not disclosed Rhythm terms.

Assume, solely for illustration, a 40% probability of the milestone payment conditional on the acquisition closing, and a 10% annual discount rate for that payment. Its probability-weighted value at closing would be approximately $14 × 40% ÷ 1.10³ = $4.21. Adding the assumed $120 initial payment gives $124.21 conditional on closing, rather than the $134 maximum.

That calculation still excludes the chance that the acquisition never closes, the wait until closing, taxes and transaction-specific rights. The assumed probabilities and discount rate are not estimates for Rhythm. They illustrate why maximum consideration, conditional expected value and a current share price answer different questions.

A premium is not an allowance for the stock to rise

An acquirer may offer more than the unaffected trading price to persuade shareholders to sell and to reflect the value it expects from control or integration. Investor.gov explains that tender offers commonly include a premium to encourage holders to tender.[3]

If a hypothetical stock trades at $100 before an offer of $120, a subsequent rise to $115 does not automatically add $15 to the offer. Under a fixed per-share cash agreement, the contractual price and the stock’s trading price remain separate. Negotiating pressure or a competing bid could lead to a revised offer, but the market move does not itself rewrite the terms.

Nor should an investor add the stock-market value to the full value of the pipeline and operating assets. Equity ownership already represents a claim on the company’s assets and future business after relevant obligations. Doing both would count the same economics twice.

Rhythm’s earlier transaction asks a related question

On November 2, Rhythm announced additional fixed payments totaling $350 million over four years to LG Chem in exchange for a lower base royalty on its MC4R portfolio, covering setmelanotide, bivamelagon and RM-718. The announced 1% rate starts on the earlier of January 1, 2029 or bivamelagon’s first commercial sale, subject to the agreement’s terms.[4]

That arrangement changes how much of eligible future sales Rhythm can retain. A potential acquirer would need to assess the retained economics alongside remaining payment commitments, development spending and financing obligations. The proximity of the two stories does not establish that the royalty amendment was designed to facilitate a sale.

For the reported acquisition approach, the next useful evidence is a statement from the parties or transaction documents specifying consideration, conditions and obligations. Until then, the gap between a trading price and $134 cannot be read as a contractually secured return.

The question is not simply how large the headline number is. It is which payments could become enforceable, under what conditions, and after how much time.

Sources and scope

[1] Reuters, November 4, 2026: reported AstraZeneca approach for Rhythm.

[2] Investor.gov: Mergers. For an example of conditions and termination provisions in a signed agreement: SEC-filed merger disclosure. These sources explain transaction mechanics and do not establish Rhythm’s proposed terms.

[3] Investor.gov: Tender Offer.

[4] Rhythm, November 2, 2026: LG Chem agreement amendment.

Information reviewed through November 6, 2026. The article does not claim access to an executed acquisition agreement or private offer documents. Illustrative figures are not an estimate of Rhythm’s fair value, a reconstruction of the reported offer, or a trading recommendation.